论文信息 - Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. - 字舞流文

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

C. Coens | A. van den Eertwegh | V. Atkinson | M. Kicinski | D. Grebennik | M. Pe | R. Jamal | S. Sandhu | Stéphane Dalle | A. Eggermont | Andrew Haydon | D. Schadendorf | Georgina V. Long | Christian U. Blank | Piotr Rutkowski | Mario Mandalá | Caroline Robert | Emanuel Bührer | Adnan Khattak | Matteo S. Carlino | Andrey Meshcheryakov | Susana Puig | C. Krepler